PMID- 34616674
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced 
      Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI.
PG  - 700023
LID - 10.3389/fonc.2021.700023 [doi]
LID - 700023
AB  - PURPOSE: Platinum-based chemotherapy remains the classic treatment option for 
      patients with advanced non-small-cell lung cancer (NSCLC) who progress while 
      receiving treatment with epidermal growth factor receptor-tyrosine kinase 
      inhibitors (EGFR-TKIs). In this study, we analyzed real-world outcomes of 
      treatment with immune checkpoint inhibitors (ICIs) combined with platinum-free 
      chemotherapy in patients with NSCLC after developing resistance to EGFR-TKIs. 
      METHODS: This retrospective study included patients with mutation-positive NSCLC 
      after developing resistance to EGFR-TKIs. Patients who received chemotherapy 
      alone plus ICIs with or without anti-angiogenic drugs (cohort A) or 
      platinum-based chemotherapy (cohort B) between February 2019 and August 2020 were 
      enrolled. Clinical characteristics, EGFR mutation status, response to therapy, 
      and adverse events (AEs) were retrospectively analyzed. RESULTS: Seventeen 
      patients were eligible and included in the analysis, including 8 in cohort A and 
      9 in cohort B. After a median follow-up of 7.6 months, the median 
      progression-free survival was 6.5 months [95% confidence interval (CI), 6.1 to 
      7.0] in cohort A and 3.6 months (95% CI, 1.3-5.8) in cohort B (hazard ratios, 
      0.22; 95% CI, 0.05-0.93; P = 0.039). The overall response and disease control 
      rates were 50% and 100% in cohort A, and 22% and 89% in cohort B, respectively. 
      Adverse events of grade 3 or higher occurred in 25% of the patients in cohort A 
      and in 33.3% of the patients in cohort B. CONCLUSION: ICIs plus platinum-free, 
      single-agent chemotherapy provides promising progression-free survival and 
      overall response rate benefit, along with a low rate of severe AEs in patients 
      with EGFR-TKI-resistant advanced NSCLC.
CI  - Copyright (c) 2021 Deng, Lin, Xie, Yang, Wang, Wu, Liu, Xie, Qin and Zhou.
FAU - Deng, Haiyi
AU  - Deng H
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Lin, Xinqing
AU  - Lin X
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Xie, Xiaohong
AU  - Xie X
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Yang, Yilin
AU  - Yang Y
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Wang, Liqiang
AU  - Wang L
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Wu, Jianhui
AU  - Wu J
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Liu, Ming
AU  - Liu M
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Xie, Zhanhong
AU  - Xie Z
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Qin, Yinyin
AU  - Qin Y
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
FAU - Zhou, Chengzhi
AU  - Zhou C
AD  - State Key Laboratory of Respiratory Disease, National Clinical Research Centre 
      for Respiratory Disease, Guangzhou Institute of Respiratory Health, First 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210920
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8488293
OTO - NOTNLM
OT  - epidermal growth factor receptor gene (EGFR)
OT  - immune checkpoint inhibitor
OT  - immunotherapy
OT  - non-small-cell lung cancer
OT  - single-agent chemotherapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/08 06:00
MHDA- 2021/10/08 06:01
PMCR- 2021/01/01
CRDT- 2021/10/07 06:59
PHST- 2021/04/25 00:00 [received]
PHST- 2021/09/02 00:00 [accepted]
PHST- 2021/10/07 06:59 [entrez]
PHST- 2021/10/08 06:00 [pubmed]
PHST- 2021/10/08 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.700023 [doi]
PST - epublish
SO  - Front Oncol. 2021 Sep 20;11:700023. doi: 10.3389/fonc.2021.700023. eCollection 
      2021.